Skip to main content
. 2016 Aug 31;6(8):160091. doi: 10.1098/rsob.160091

Figure 9.

Figure 9.

() Neuropeptide treatment elevates neurite growth upon camptothecin inhibition in ATF3-deficient mice. Adult wt or Atf3 mutant DRG neurons were cultured for 24 h followed by labelling for neuron-specific βIII tubulin expression. (a,b) In the absence of NGF, wt DRG neurons (a) elaborated more and longer neurites compared with neurons lacking ATF3 (b). (c,d) In the presence of NGF, Atf3 mutant (d) grew similarly to wt (c) neurons. (e,f) Camptothecin administration for 24 h reduced neurite growth of wt (e) and ATF3-deficient (f) neurons to a similar level. (g,h) Administration of the neuropeptide VIP elevated neurite growth of both wt (g) and ATF3-deficient (h) neurons in the presence of camptothecin and NGF. (i) Quantification of the entire neurite length/neuron for all conditions tested. In Atf3 mutant neurons, GRP and VIP application resulted in statistically significant relief of camptothecin-mediated neurite growth inhibition. Numbers in bars reflect independent cultures analysed. Data are presented as mean ± s.d. *p ≤ 0.05; ***p ≤ 0.001. Scale bar (a–h) = 500 µm.